<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817969</url>
  </required_header>
  <id_info>
    <org_study_id>CMG2020-05K</org_study_id>
    <nct_id>NCT04817969</nct_id>
  </id_info>
  <brief_title>Persona Ti-Nidium Post-Market Clinical Follow-up</brief_title>
  <acronym>TKA</acronym>
  <official_title>Persona® Ti-Nidium® Personalized Total Knee System A Post-Market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data Using the Persona Ti-Nidium Total Knee System and Instrumentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to evaluate overall clinical performance and safety of&#xD;
      the Persona Ti-Nidium implant in total knee arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a prospective, multicenter data collection model of the 510(k) cleared&#xD;
      Persona Ti-Nidium Total Knee System. The study will require each site to obtain institutional&#xD;
      review board (IRB) approval prior to study enrollment. All potential study subjects will be&#xD;
      required to participate in the Informed Consent Process.&#xD;
&#xD;
      All study subjects will undergo preoperative clinical evaluations prior to their total knee&#xD;
      arthroplasty. Investigators will collect clinical data for a required 10 years. Follow-up&#xD;
      clinical visits include Early Post-op, 6 months, 1 year, 2, 3, 5, 7 and 10 years&#xD;
      post-operatively.&#xD;
&#xD;
      The objective of this study is to evaluate clinical performance, benefits and safety of the&#xD;
      Persona Ti-Nidium implant in total knee arthroplasty.&#xD;
&#xD;
      Specific assessments include:&#xD;
&#xD;
        1. Confirming the long-term safety, performance and clinical benefits of the Persona&#xD;
           Ti-Nidium total knee system and instrumentation in primary and revision TKA.&#xD;
&#xD;
        2. Verifying that, under normal use, the performance and clinical benefits of this device&#xD;
           and its instrumentation conform to those intended by the manufacturer by recording&#xD;
           patient-reported clinical outcomes measures (PROMs) and radiographic outcomes (if&#xD;
           available).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 2034</completion_date>
  <primary_completion_date type="Anticipated">May 2034</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxford Knee Score (OKS)</measure>
    <time_frame>10 years</time_frame>
    <description>A patient reported functional outcome score for knee arthroplasty. This score ranges from 0-48, with higher scores indicating a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score (KSS) Expectations (pre and post op)</measure>
    <time_frame>10 years</time_frame>
    <description>This is a 3 question form regarding a patient's expectations of the total knee replacement. The pre-op form assesses the patient's expectations of the knee replacement, and the post-op form addresses how the replacement is meeting said expectations. The score ranges from 3-15, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Five Dimension Five Level (EQ-5D-5L) Outcomes Measure</measure>
    <time_frame>10 years</time_frame>
    <description>A questionnaire completed by the patient and assesses his/her general health status. This score ranges from -0.573 to 1, with higher recorded scores indicating better overall health.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Knee Pain Chronic</condition>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Traumatic Arthritis</condition>
  <condition>Polyarthritis</condition>
  <condition>Varus Deformity</condition>
  <condition>Valgus Deformity</condition>
  <condition>Flexion Deformity of the Knee</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Patellofemoral Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Persona Ti-Nidium</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zimmer Biomet Persona Ti-Nidium Total Knee System</intervention_name>
    <description>Primary Knee Total Arthroplasty</description>
    <arm_group_label>Persona Ti-Nidium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is of legal age and skeletally mature&#xD;
&#xD;
          2. Patient is willing and able to provide written Informed Consent by signing and dating&#xD;
             the IRB-approved Informed Consent document&#xD;
&#xD;
          3. Patient is willing and able to complete scheduled follow-up evaluations as defined in&#xD;
             the study protocol&#xD;
&#xD;
          4. Patient qualifies for total knee arthroplasty based upon physical exam and medical&#xD;
             history, and meets the approved indications for use of the Persona Ti-Nidium Knee&#xD;
             System and Vivacit-E polyethylene articulating surface&#xD;
&#xD;
          5. Independent of study participation, patient is a candidate for the commercially&#xD;
             available Persona Ti-Nidium Knee and Vivacit-E polyethylene articulating surface,&#xD;
             implanted in accordance with product labeling&#xD;
&#xD;
        Study Device Inclusion Criteria:&#xD;
&#xD;
        The Persona Ti-Nidium Total Knee is intended for patients with severe pain and disability&#xD;
        due to the following:&#xD;
&#xD;
          1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.&#xD;
&#xD;
          2. Collagen disorders, and/or avascular necrosis of the femoral condyle.&#xD;
&#xD;
          3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral&#xD;
             erosion, dysfunction or prior patellectomy.&#xD;
&#xD;
          4. Moderate valgus, varus, or flexion deformities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is unwilling to sign the Informed Consent&#xD;
&#xD;
          2. Patient is currently participating in any other surgical intervention or pain&#xD;
             management study&#xD;
&#xD;
          3. Patient is pregnant or considered a member of a protected (vulnerable) population&#xD;
             whose inclusion in the study is inappropriate (e.g. prisoner, mentally incompetent)&#xD;
&#xD;
          4. Patient has a mental or neurologic condition who is unwilling or incapable of&#xD;
             following postoperative care instructions&#xD;
&#xD;
          5. Patient has a condition which would, in the judgement of the Investigator, place the&#xD;
             patient at undue risk or interfere with the conduct of the study&#xD;
&#xD;
          6. Patient is institutionalized or is a known drug abuser, a known alcoholic or cannot&#xD;
             understand the requirements of study participation&#xD;
&#xD;
        Study Device Exclusion Criteria&#xD;
&#xD;
          1. Previous history of infection in the affected joint and/or other local/systematic&#xD;
             infection that may affect the prosthetic joint&#xD;
&#xD;
          2. Insufficient bone stock on femoral or tibial surfaces&#xD;
&#xD;
          3. Skeletal immaturity&#xD;
&#xD;
          4. Neuropathic arthropathy&#xD;
&#xD;
          5. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the&#xD;
             affected limb&#xD;
&#xD;
          6. A stable, painless arthrodesis in a satisfactory functional position&#xD;
&#xD;
          7. Severe instability secondary to the absence of collateral ligament integrity&#xD;
&#xD;
          8. Rheumatoid arthritis (RA) accompanied by an ulcer of the skin or a history of&#xD;
             recurrent breakdown of the skin&#xD;
&#xD;
          9. The kinematic alignment surgical technique is contraindicated for patients with&#xD;
             greater than 5° valgus deformity with medial collateral ligament (MCL) insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kacy Arnold, RN, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Affairs Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Swanson</last_name>
    <phone>5745497606</phone>
    <email>tim.swanson@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Jaggard</last_name>
    <phone>3172603841</phone>
    <email>Charles.Jaggard@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Denver Hip &amp; Knee, Inc.</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Gridley</last_name>
      <phone>303-925-4750</phone>
      <email>acrafferty@msn.com</email>
    </contact>
    <investigator>
      <last_name>Derek Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mississippi Sports Medicine and Orthopaedic Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Parsell</last_name>
      <email>dparsell@msmoc.com</email>
    </contact>
    <investigator>
      <last_name>Kerk Mehrle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevor Pickering, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Almand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Orthopaedic Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Munson</last_name>
      <email>MunsonNR@nmortho.net</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Albrecht</last_name>
      <email>AlbrechtKM@nmortho.net</email>
    </contact_backup>
    <investigator>
      <last_name>Krishna Tripuraneni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Racca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Carothers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Landon Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Total Knee Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

